盐酸地芬尼多片的有关物质分析

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (50 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the consistency of related substances between the domestically marketed Difenidol Hydrochloride Tablets and reference preparations.Methods The related substances of Difenidol Hydrochloride Tablets were determined and evaluated according to the official quality standard recorded in Pharmacopoeia of the People′s Republic(2015 edition,version 2).The forced degradation test was also carried out.Results The detection limit of impurityⅠwas 2.8 ng,and the quantitative limit was 9.7 ng.The solution of Difenidol Hydrochloride was stable in 18 hours,and the relative standard deviation (RSD)of impurities and main peak area was less than 2%.The linearity range of impurityⅠwas 0.4829-48.2900μg/ml(R2=1).In the precision test of impurityⅠ,the RSD of peak area was 4.2%(n=12).The average recovery of impurityⅠ(n=6)was 102.6%,and RSD was 2.0%.No impurities were detected in two batch tablets of the first domestic manufacturer.The content of impuritiesⅠwas 0.14%in another batch.No impurities were detected in two batch tablets of the original manufacturer.The content of impuritiesⅠwas 0.10%in another batch.The content of impuritiesⅠwas among 0.2%-0.5%in the other three domestic manufacturers′tablets.Under the conditions of light,oxidation,heat and alkaline damage,there was no significant change in the related substances between the first domestic imitator and the original manufacturer′s tablets.Under the acid damage condition,the degradation of the main peak was 15%,and the increase of impurityⅠwas 15%.Conclusion Impurity profiling of the first generic preparations is consistent with the reference preparations.For other three domestic manufacturers,impurityⅠcontent is 2-5 times higher than that of the reference preparations.

Key words： Difenidol Hydrochloride Tablets Related substances High performance liqiud chromatography Difenidol Hydrochloride

Received: 21 January 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Min-min TANG Xiao-peng WU Ze-jun LIU Shui-ping▲ WANG Xi

Cite this article:

CHEN Min-min TANG Xiao-peng WU Ze-jun LIU Shui-ping▲ WANG Xi. Analysis of related substances in Difenidol Hydrochloride Tablets[J]. 中国当代医药, 2020, 27(24): 41-45.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I24/41

[5]	于晓雯，董敏，由春娜.仿制药一致性评价对低价、短缺药品的影响分析及对策建议[J].中国医药工业杂志，2018，49（8）：1182-1190.
[6]	石靖，许真玉.口服固体制剂一致性评价质量研究和体外评价的常见问题分析[J].中国新药杂志，2019，28（20）：2473-2477.
[7]	黄仲义，李光慧.仿制药质量一致性评价及有关建议[J].上海医药，2019，40（7）：3-5.
[8]	曹凤习.RP-HPLC测定盐酸地芬尼多原料的有关物质[J].中国现代应用药学杂志，2009，8（26）：3914-3915.
[9]	曹凤习，杜增辉，周建敏.RP-HPLC测定盐酸地芬尼多片的含量与有关物质[J].中国药学杂志，2009，44（22）：1748-1751.
[2]	吴芬，郭真君，曾媛，等.盐酸地芬尼多的研究进展[J].中国药师，2019，22（7）：1323-1328.
[3]	唐小鹏，陈莉，陈珉珉，等.盐酸地芬尼多片体外溶出一致性评价研究[J].食品与药品，2018，20（2）：132-135.
[4]	杨庆，刘玲玲，周斌.我国仿制药一致性评价沿革及评价方法分析[J].中国医药工业杂志，2019，50（3）：338-344.
[1]	国家药典委员会.中华人民共和国药典[S].2015年版二部.北京：化学工业出版社，2015：929-930.
[10]	张西如.高效液相色谱-电喷雾电离-质谱法分析盐酸地芬尼多的相关物质[J].中国药业，2010，10（19）：41-42.
[11]	曹凤习.HPLC测定盐酸地芬尼多片中杂质的含量[J].中国药师，2011，14（2）：203-205.
[12]	曹凤习，刘晖，靳茂礼，等.盐酸地芬尼多杂质烯化合物的制备及结构确证[J].中国药业，2013，22（20）：34-35.
[13]	耿韫，郄冰冰.盐酸地芬尼多片质量分析[J].河北医药，2017，39（17）：2699-2702.
[14]	王景欣，仇俊新，丁平田.阿莫西林克拉维酸钾片仿制制剂与参比制剂杂质谱对比分析[J].中国药剂学杂志，2019，17（4）：115-121.
[15]	黄春青，唐永强，黄翰林，等.国产吲哚美辛胶囊和吲哚美辛缓释胶囊有关物质分析评价[J].中国新药杂志，2019，28（18）：2285-2290.
[16]	张迪，李尚颖，孙苓苓.氟康唑胶囊的质量分析与评价[J].中南药学，2019，17（7）：1119-1123.
[17]	国家药典委员会.中华人民共和国药典[S].2015年版四部.北京：化学工业出版社，2015：354-356.
[18]	杭太俊.药物分析[M].8版.北京：人民卫生出版社，2016：136-138.
[19]	日本药局方编辑委员会.日本药典17版[S].2017：791-792.
[20]	韩国药典委员会.韩国药典第10版[S].2010：444.